ArticleBMC medicine2026
Single-cell profiling of gastric cancer ascites reveals an epithelial-immune dual phenotype signature predictive for anti-PD-1 immunotherapy responses.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGastric cancer (GC) with peritoneal metastasis frequently leads to malignant ascites (MA), a highly immunosuppressive "liquid tumor microenvironment" associated with poor prognosis. Although immune checkpoint blockade (ICB) demonstrate efficacy in some GC patients, treatment response to gastric cancer-associated peritoneal metastasis (GCPM) remains heterogeneous. The immune mechanisms driving this variability and predictive biomarkers remain unclear.
methodsWe performed single-cell transcriptomics and TCR/BCR repertoire analyses on paired MA and peripheral blood mononuclear cell (PBMC) samples from 10 advanced GC patients. Cellular clustering, trajectory inference, and intercellular communication analyses characterized immune remodeling. Clinical cohorts were used to validate prognostic and therapeutic predictive significance.
resultsImmune landscape of GCMA was delineated, which unveils extensive remodeling of T cells, B cells, and myeloid lineages. Notably, we identified a novel epithelial-immune dual-phenotype cell (EIDPC) population, validated by single-cell RNA sequencing and flow cytometry, exhibiting moderate malignant characteristics and potent immunoregulatory capacity. Transcriptomic and trajectory analyses suggest an epithelial origin with reprogramming toward immune evasion. Based on 10 EIDPC core genes, we developed the immune response signature of EIDPC (IRS-EIDPC), which accurately predicts anti-PD-1 therapy response and prognosis in independent gastric cancer cohort (AUC 0.929).
conclusionsThis study reveals the immune landscape of malignant ascites in gastric cancer, and confirms EIDPC as a transitional malignant subpopulation with potent immunomodulatory functions. The IRS-EIDPC signature may aid in predicting immunotherapy responses and survival outcomes, provides insights into immune plasticity in malignant gastric ascites, and may help inform future precision therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.